Alterity Therapeutics Files 6-K for Security Issuance
Ticker: PRNAF · Form: 6-K · Filed: Jul 18, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Jul 18, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: securities-offering, registration-statement, filing-update
Related Tickers: ATH
TL;DR
ATH files 6-K, looks like they're planning to issue more stock.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on July 18, 2024, to incorporate by reference into several of its existing Registration Statements on Form S-8 and Form F-3. The filing includes Exhibit 99.1, which details a proposed issue of securities for ATH.
Why It Matters
This filing indicates potential future capital raising or stock-based compensation activities for Alterity Therapeutics, which could impact its share structure and financial resources.
Risk Assessment
Risk Level: medium — The filing relates to a proposed security issuance, which can introduce dilution or signal funding needs, impacting investor confidence.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- ATH (company) — Ticker symbol for Alterity Therapeutics
- Form S-8 (document) — Registration Statement type
- Form F-3 (document) — Registration Statement type
- Exhibit 99.1 (document) — Details proposed security issue
FAQ
What is the purpose of incorporating this 6-K into existing registration statements?
The Form 6-K is being incorporated by reference into Alterity Therapeutics' Registration Statements on Form S-8 and Form F-3, suggesting it relates to securities offerings or employee stock plans covered by those statements.
What specific information is contained in Exhibit 99.1?
Exhibit 99.1 details a proposed issue of securities for ATH (Alterity Therapeutics).
When was this Form 6-K filed?
This Form 6-K was filed on July 18, 2024.
What is Alterity Therapeutics Limited's principal executive office address?
Alterity Therapeutics Limited's principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?
Alterity Therapeutics indicates it files annual reports under Form 20-F.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2024-07-18 08:00:41
Filing Documents
- ea0209617-6k_alterity.htm (6-K) — 13KB
- ea020961701ex99-1_alterity.htm (EX-99.1) — 38KB
- ex99-1_001.jpg (GRAPHIC) — 1KB
- 0001213900-24-062314.txt ( ) — 54KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Proposed issue of securities - ATH 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: July 18, 2024 2